The endowment's consistent selling pattern suggests ongoing portfolio rebalancing rather than a negative view on Lilly. Monitor future Form 144 and Form 4 filings for any acceleration in selling pace, which could signal a change in the endowment's long-term holding strategy.
LLY drugs
LLY drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Oct 30 $1,417.54entry
- T+1 · 15d ago −0.46%α +0.02% · $1,410.99
- T+5 · 11d ago −4.48%α −1.78% · $1,354.00
- T+11 · todayOpen
- T+20 · in 13d Pending
- T+60 · in 2mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Lilly Endowment Inc., the company's largest shareholder with a $108.4B stake, filed a Form 144 notice of intent to sell 295,000 shares of Eli Lilly common stock, valued at approximately $405 million based on the filing date. The endowment has been actively selling shares in recent months, with prior sales totaling over $1.1 billion since August 2026. This is a routine portfolio rebalancing by a long-term charitable holder, not an insider trading signal.
Key Facts
- Lilly Endowment Inc. intends to sell 295,000 shares of Eli Lilly common stock.
- Estimated value of the proposed sale is $405,241,500 based on the filing.
- The endowment has sold approximately 1,007,403 shares in four separate transactions since August 2026, totaling over $1.1 billion.
- Lilly Endowment is the largest institutional holder with a $108.4B stake as of Q2 2026.
- The sale represents about 0.37% of the endowment's total holdings, a small fraction.
Financial Impact
Proposed sale of 295,000 shares valued at ~$405 million, representing ~0.03% of LLY's $1.21 trillion market cap.
Risk Factors
- Form 144 is an intent to sell; the actual sale may not occur or may be at different terms.
- Continued large-scale selling by the endowment could create modest downward pressure on the stock.
- No material change in company fundamentals is indicated by this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0000316011-26-000040 |
| Document: 0000316011-26-000040-index.html | 0000316011-26-000040 |
| Document: 0000316011-26-000040.txt | 0000316011-26-000040 |
Track record
23 reports on LLY
7 of 8 bullish or bearish reports moved the stock their way by T+1. Best: +31.53% at T+60 after the Apr 16, 2026 report. 8 of 8 went positive at some point.
Filters
- Oct 30, 202617d ago 144 Neutral 3/10 Viewing Entry $1,417.54 to $1,410.99 Now $1,431.67 +1.00% ▼ −0.46% +0.02% vs SPY
- Oct 29, 202618d ago 8-K Bullish 6/10 Entry $1,373.70 to $1,417.54 Now $1,431.67 +4.22% ▲ +3.19% +4.96% vs SPY
- Oct 26, 202621d ago Press Release Neutral 2/10 Entry $1,279.14 to $1,281.91 Now $1,431.67 +11.92% ▲ +0.22% −0.34% vs SPY
- Oct 26, 202622d ago Court Ruling Neutral 3/10 Entry $1,281.91 to $1,288.30 Now $1,431.67 +11.68% ▲ +0.50% +0.15% vs SPY
- Oct 19, 202628d ago SC 13G/A Neutral 3/10 Entry $1,240.34 to $1,283.66 Now $1,431.67 +15.43% ▲ +3.49% +3.16% vs SPY
- Oct 16, 20264w ago Institutional Cluster Bullish 4/10 Entry $1,240.34 to $1,283.66 Now $1,431.67 +15.43% ▲ +3.49% +3.16% vs SPY
- Oct 15, 20264w ago Press Release Neutral 1/10 Entry $1,251.61 to $1,257.03 Now $1,431.67 +14.39% ▲ +0.43% +1.54% vs SPY
- Oct 7, 20265w ago 144 Neutral 3/10 Entry $1,188.72 to $1,169.60 Now $1,431.67 +20.44% ▼ −1.61% −1.19% vs SPY
- Sep 11, 20269w ago Press Release Bullish 5/10 Entry $1,115.70 to $1,138.28 Now $1,431.67 +28.32% ▲ +2.02% +2.47% vs SPY
- Sep 8, 202610w ago Court Ruling Neutral 4/10 Entry $1,124.21 to $1,123.00 Now $1,431.67 +27.35% ▼ −0.11% +0.49% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers